• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nkarta Inc.

    4/23/26 4:41:50 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTX alert in real time by email
    DEFA14A 1 ny20064125x2_defa14a.htm DEFA14A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
     
     
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
     
    Check the appropriate box: 
    ☐
    Preliminary Proxy Statement
    ☐ 
    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ 
    Definitive Proxy Statement
    ☒ 
    Definitive Additional Materials
    ☐ 
    Soliciting Material Under §240.14a-12
     
    NKARTA, INC.
     (Name of Registrant as Specified In Its Charter)

    Not applicable

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
     
    Payment of Filing Fee (Check all boxes that apply):
     
    ☒ 
    No fee required
    ☐ 
    Fee paid previously with preliminary materials.
    ☐ 
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



     Your Vote Counts!  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  V92834-P46732  *Please check the meeting materials for any special requirements for meeting attendance.  NKARTA, INC.  1150 VETERANS BOULEVARD SOUTH SAN FRANCISCO, CA 94080  NKARTA, INC.  2026 Annual Meeting  Vote by June 9, 2026  11:59 PM ET  You invested in NKARTA, INC. and it’s time to vote!  You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the  availability of proxy materials for the stockholder meeting to be held on June 10, 2026.  Get informed before you vote  View the Notice & Proxy Statement and 2025 Annual Report to stockholders online OR you can receive a free paper or email copy of  the material(s) by making a request prior to May 27, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call toll-free 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.  Vote Virtually at the Meeting*  June 10, 2026  1:00 p.m., Pacific Time  www.virtualshareholdermeeting.com/NKTX2026  Vote Before the Meeting  at ProxyVote.com by June 9, 2026 11:59 PM ET 
     

     Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT  This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters.  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  1. Election of two directors to serve until the company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified:  For All  Ali Behbahani, M.D., M.B.A.  Zachary Scheiner, Ph.D.  2. Ratification of the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending December 31, 2026.  For  3. Advisory approval of the compensation paid to the company’s named executive officers, as disclosed in the proxy statement.  For  4. Advisory vote on the frequency of future advisory votes on executive compensation.  1 Year  NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof.  Voting Items  Board Recommends  V92835-P46732 
     

    Get the next $NKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NKTX

    DatePrice TargetRatingAnalyst
    5/15/2025Outperform → Mkt Perform
    William Blair
    10/9/2024$14.00Buy
    Rodman & Renshaw
    8/14/2024$16.00Outperform → Strong Buy
    Raymond James
    3/22/2024$13.00 → $16.00Strong Buy → Outperform
    Raymond James
    12/22/2022Outperform → Perform
    Oppenheimer
    10/10/2022$25.00Buy
    Canaccord Genuity
    7/28/2022$26.00Buy
    Needham
    7/18/2022$30.00Outperform
    SVB Leerink
    More analyst ratings

    $NKTX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Nkarta Inc.

    DEFA14A - Nkarta, Inc. (0001787400) (Filer)

    4/23/26 4:41:50 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Nkarta Inc.

    DEF 14A - Nkarta, Inc. (0001787400) (Filer)

    4/23/26 4:41:05 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Nkarta Inc.

    EFFECT - Nkarta, Inc. (0001787400) (Filer)

    4/6/26 12:15:16 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nkarta downgraded by William Blair

    William Blair downgraded Nkarta from Outperform to Mkt Perform

    5/15/25 8:09:11 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Nkarta with a new price target

    Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00

    10/9/24 7:55:21 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta upgraded by Raymond James with a new price target

    Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00

    8/14/24 7:45:34 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hastings Paul J sold $53,915 worth of shares (26,046 units at $2.07), decreasing direct ownership by 6% to 390,023 units (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/20/26 5:39:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Mahmood Nadir sold $11,693 worth of shares (5,649 units at $2.07), decreasing direct ownership by 3% to 167,727 units (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/20/26 5:38:03 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Rose Shawn Marshall was granted 70,000 shares (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/8/26 5:50:36 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

    Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis cohort to be added to Ntrust-2Dosing continues at 4 billion cell dose level (12 billion cells in 3-dose cycle) with initial data expected to be presented at a medical meeting this year SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1

    4/15/26 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta to Participate in Needham Virtual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference. At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, "Cell Therapy in Autoimmune: State of the Art and What Comes Next." Later that afternoon, Nkarta President Nadir Mahmood will participate in a 3:45 p.m ET fireside chat to share updates on the company's investigational CAR-NK cell therapy to treat B cell-mediated auto

    4/9/26 7:00:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

    Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026Cash balance of $295.1 million on December 31, 2025, including cash, cash equivalents and investments, is expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. "2025 was a ye

    3/25/26 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    3/29/24 5:38:04 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    3/28/24 4:30:06 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

    SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought

    6/6/25 8:52:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

    Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025

    5/14/25 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

    SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as

    7/16/24 6:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 4:05:12 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 8:55:31 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Financials

    Live finance-specific insights

    View All

    Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

    New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil

    10/17/23 7:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

    SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart

    10/16/23 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic

    6/27/23 7:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care